Recalls
When you take money from everyone
Is it no longer a conflict of interest?
I only raise the question this morning after reading the latest in the ongoing dust-up over implanted defibrillators, where the latest company on the hot seat for selling flawed devices (St. Jude Medical) has accused the scientist who brought the situation to light — Dr. Robert Hauser of the Minneapolis Heart Institute Foundation — of undercounting the deaths associated with their main rivals’ devices. Why does the metaphor “falling out among thieves” come to mind?
Heart doc on St. Jude, MDT Riata fight: “I can’t recall seeing a more contentious” dispute
The kerfluffle over a study linking 22 deaths to St. Jude Medical‘s (NYSE:STJ) recalled Riata defibrillator leads picked up a new player: Ohio cardiologist Dr. Edward Schloss.
MassDevice.com +3 | The top 3 med-tech stories for April 10, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
St. Jude, firing back, posts 377 Medtronic Quattro lead deaths
The editor of the Heart Rhythm Society’s journal is sticking to his guns and refusing to retract an article linking some 22 deaths with St. Jude Medical’s (NYSE:STJ) recalled Riata defibrillator leads, despite the med-tech giant’s insistence that the study contains fundamental factual errors.
Hearth Rhythm Society won’t retract Riata piece
The editor of the Heart Rhythm Society journal is sticking by his guns and refusing to retract an article linking some 22 deaths with St. Jude Medical‘s (NYSE:STJ) recalled Riata defibrillator leads.
FDA looks to strengthen device surveillance post-Riata | MassDevice.com On Call
MASSDEVICE ON CALL — Under increasing pressure from doctors, the FDA this month will unveil a new medical device post-market surveillance program aimed at better tracking potentially faulty devices.
The more rigorous program will include unique device identifiers that allow the FDA, doctors and manufacturers to track individual devices and better monitor, track and report defects.
MassDevice.com +3 | The top 3 med-tech stories for April 9, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Medtronic confirms Hauser’s findings
St. Jude, on the attack, calls out Medtronic for “whisper campaign”
St. Jude Medical (NYSE:STJ) accused arch-rival Medtronic (NYSE:MDT) of a whisper campaign to discredit its newer Durata defibrillator leads, as part of its ongoing assault against critics of its recalled Riata defibrillator leads.
David vs. Goliath: St. Jude Medical seeks retraction of Heart Rhythm Journal manuscript
St. Jude Medical, a widely-used manufacturer of implantable cardiac devices, finds they have a bit of a problem with a form of insulation that surrounds wires contained in several lines of their pacing and defibrillator leads. They decide to pull these products from the market after substantial evidence that their leads’ reliability falls below their standards.